Pyxis Oncology (PYXS) Cash & Current Investments (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Cash & Current Investments data on file, last reported at $66.9 million in Q4 2025.

• On a quarterly basis, Cash & Current Investments fell 47.33% year-over-year to $66.9 million in Q4 2025; TTM through Dec 2025 was $66.9 million, a 47.33% decrease from a year earlier, with the FY2025 full-year figure at $66.9 million, down 47.33% from the prior year.
• Cash & Current Investments for Q4 2025 stood at $66.9 million, down from $76.3 million in the prior quarter.
• Over the last five years, Cash & Current Investments for PYXS reached as high as $276.2 million in Q4 2021 and fell as low as $12.2 million in Q2 2025.
• Historically, Cash & Current Investments has averaged $118.9 million across 5 years, with a median of $129.9 million in 2023.
• Across the five-year window, Cash & Current Investments jumped 1086.88% in 2021 and tumbled 87.83% in 2023, its largest moves.
• Year by year, Cash & Current Investments stood at $276.2 million in 2021, then tumbled by 34.55% to $180.8 million in 2022, then slumped by 34.0% to $119.3 million in 2023, then advanced by 6.4% to $126.9 million in 2024, then tumbled by 47.33% to $66.9 million in 2025.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $66.9 million in Q4 2025, $76.3 million in Q3 2025, and $12.2 million in Q2 2025.